These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 19360338)
1. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Zimmermann M; Armeanu S; Smirnow I; Kupka S; Wagner S; Wehrmann M; Rots MG; Groothuis GM; Weiss TS; Königsrainer A; Gregor M; Bitzer M; Lauer UM Int J Oncol; 2009 May; 34(5):1247-56. PubMed ID: 19360338 [TBL] [Abstract][Full Text] [Related]
2. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
3. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis. Lampe J; Bossow S; Weiland T; Smirnow I; Lehmann R; Neubert W; Bitzer M; Lauer UM Gene Ther; 2013 Nov; 20(11):1033-41. PubMed ID: 23719065 [TBL] [Abstract][Full Text] [Related]
4. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881 [TBL] [Abstract][Full Text] [Related]
5. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536 [TBL] [Abstract][Full Text] [Related]
6. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. Zimmermann M; Weiland T; Bitzer M; Lauer UM Methods Mol Biol; 2012; 806():121-36. PubMed ID: 22057449 [TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. Hartkopf AD; Bossow S; Lampe J; Zimmermann M; Taran FA; Wallwiener D; Fehm T; Bitzer M; Lauer UM Gynecol Oncol; 2013 Aug; 130(2):362-8. PubMed ID: 23676551 [TBL] [Abstract][Full Text] [Related]
8. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Mühlebach MD; Schaser T; Zimmermann M; Armeanu S; Hanschmann KM; Cattaneo R; Bitzer M; Lauer UM; Cichutek K; Buchholz CJ Cancer Res; 2010 Oct; 70(19):7620-9. PubMed ID: 20858718 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948 [TBL] [Abstract][Full Text] [Related]
10. Advantages of using recombinant measles viruses expressing a fluorescent reporter gene with vibratome slice technology in experimental measles neuropathogenesis. Ludlow M; Duprex WP; Cosby SL; Allen IV; McQuaid S Neuropathol Appl Neurobiol; 2008 Aug; 34(4):424-34. PubMed ID: 17986184 [TBL] [Abstract][Full Text] [Related]
11. Primary resistance phenomena to oncolytic measles vaccine viruses. Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Myers R; Greiner S; Harvey M; Soeffker D; Frenzke M; Abraham K; Shaw A; Rozenblatt S; Federspiel MJ; Russell SJ; Peng KW Cancer Gene Ther; 2005 Jul; 12(7):593-9. PubMed ID: 15746945 [TBL] [Abstract][Full Text] [Related]
13. Selective in vitro cytotoxic effect of human cancer cells by bluetongue virus-10. Hu J; Dong CY; Li JK; Chen DE; Liang K; Liu J Acta Oncol; 2008; 47(1):124-34. PubMed ID: 17851866 [TBL] [Abstract][Full Text] [Related]
14. Modeling of cancer virotherapy with recombinant measles viruses. Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099 [TBL] [Abstract][Full Text] [Related]
15. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Pan QW; Zhong SY; Liu BS; Liu J; Cai R; Wang YG; Liu XY; Qian C Acta Pharmacol Sin; 2007 Dec; 28(12):1996-2004. PubMed ID: 18031615 [TBL] [Abstract][Full Text] [Related]
16. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868 [TBL] [Abstract][Full Text] [Related]
17. Persistent measles virus infection of mouse neural cells lacking known human entry receptors. Abdullah H; Earle JA; Gardiner TA; Tangy F; Cosby SL Neuropathol Appl Neurobiol; 2009 Oct; 35(5):473-86. PubMed ID: 19490430 [TBL] [Abstract][Full Text] [Related]
18. Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene. Yurttas C; Berchtold S; Malek NP; Bitzer M; Lauer UM Hum Gene Ther Clin Dev; 2014 Jun; 25(2):85-96. PubMed ID: 24933569 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Peng KW; Facteau S; Wegman T; O'Kane D; Russell SJ Nat Med; 2002 May; 8(5):527-31. PubMed ID: 11984600 [TBL] [Abstract][Full Text] [Related]
20. Passage in Vero cells alters the characteristics of measles AIK-C vaccine strain. Uejima H; Nakayama T; Komase K Vaccine; 2006 Feb; 24(7):931-6. PubMed ID: 16176848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]